Trial Profile
A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Community-acquired pneumonia; Pneumococcal infections
- Focus Therapeutic Use
- Acronyms CAPiTA
- Sponsors Pfizer
- 30 May 2019 Results of post-hoc analysis assessing serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia published in the Vaccine
- 16 Apr 2019 Results of post hoc analysis assessing the utility of adult pneumococcal conjugate vaccine (PCV) programs presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 31 May 2018 Results of post hoc analysis evaluating efficacy published in the Vaccine